Eli Wallace
Io Therapeutics (United States)(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Melanoma and MAPK Pathways, Nitric Oxide and Endothelin Effects, Microtubule and mitosis dynamics, Cancer Mechanisms and Therapy
Most-Cited Works
- → Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor(2007)582 cited
- → Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation(2011)76 cited
- → Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy(2005)70 cited
- → Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor(2010)37 cited
- → Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C(2024)35 cited
- → Diaminoindanes as Microsomal Triglyceride Transfer Protein Inhibitors(2001)32 cited
- → Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo(2011)25 cited
- Abstract #1795: In Vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2.(2009)
- → Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR(2024)20 cited
- Preclinical development of ARRY-142886, a potent and selective MEK inhibitor(2004)